Cargando…

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients

Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Hiroki, Kita, Ryuichi, Kimura, Toru, Ohara, Yoshiaki, Takeda, Haruhiko, Sakamoto, Azusa, Saito, Sumio, Nishijima, Norihiro, Nasu, Akihiro, Komekado, Hideyuki, Osaki, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107235/
https://www.ncbi.nlm.nih.gov/pubmed/25057310
http://dx.doi.org/10.7150/jca.9413
_version_ 1782327569350131712
author Nishikawa, Hiroki
Kita, Ryuichi
Kimura, Toru
Ohara, Yoshiaki
Takeda, Haruhiko
Sakamoto, Azusa
Saito, Sumio
Nishijima, Norihiro
Nasu, Akihiro
Komekado, Hideyuki
Osaki, Yukio
author_facet Nishikawa, Hiroki
Kita, Ryuichi
Kimura, Toru
Ohara, Yoshiaki
Takeda, Haruhiko
Sakamoto, Azusa
Saito, Sumio
Nishijima, Norihiro
Nasu, Akihiro
Komekado, Hideyuki
Osaki, Yukio
author_sort Nishikawa, Hiroki
collection PubMed
description Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE. Methods: Clinical outcomes, including overall survival (OS) and tumor response rate at initial therapy, were compared between these two groups. Results: The median survival time and the 1- and 3-year cumulative OS rates were 2.90 years and 84.1% and 48.0%, respectively, in the elderly group and 2.44 years and 78.2% and 39.3%, respectively, in the control group (p=0.887). The objective response rate in the elderly group was 81.8% (54/66 patients), while that in the control group was 78.6% (66/84 patients) (p=0.227). Conclusion: Elderly patients with intermediate HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate HCC undergoing TACE.
format Online
Article
Text
id pubmed-4107235
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-41072352014-07-23 Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients Nishikawa, Hiroki Kita, Ryuichi Kimura, Toru Ohara, Yoshiaki Takeda, Haruhiko Sakamoto, Azusa Saito, Sumio Nishijima, Norihiro Nasu, Akihiro Komekado, Hideyuki Osaki, Yukio J Cancer Research Paper Aim: The aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE. Methods: Clinical outcomes, including overall survival (OS) and tumor response rate at initial therapy, were compared between these two groups. Results: The median survival time and the 1- and 3-year cumulative OS rates were 2.90 years and 84.1% and 48.0%, respectively, in the elderly group and 2.44 years and 78.2% and 39.3%, respectively, in the control group (p=0.887). The objective response rate in the elderly group was 81.8% (54/66 patients), while that in the control group was 78.6% (66/84 patients) (p=0.227). Conclusion: Elderly patients with intermediate HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate HCC undergoing TACE. Ivyspring International Publisher 2014-07-17 /pmc/articles/PMC4107235/ /pubmed/25057310 http://dx.doi.org/10.7150/jca.9413 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Nishikawa, Hiroki
Kita, Ryuichi
Kimura, Toru
Ohara, Yoshiaki
Takeda, Haruhiko
Sakamoto, Azusa
Saito, Sumio
Nishijima, Norihiro
Nasu, Akihiro
Komekado, Hideyuki
Osaki, Yukio
Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title_full Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title_fullStr Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title_full_unstemmed Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title_short Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
title_sort transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107235/
https://www.ncbi.nlm.nih.gov/pubmed/25057310
http://dx.doi.org/10.7150/jca.9413
work_keys_str_mv AT nishikawahiroki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT kitaryuichi transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT kimuratoru transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT oharayoshiaki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT takedaharuhiko transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT sakamotoazusa transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT saitosumio transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT nishijimanorihiro transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT nasuakihiro transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT komekadohideyuki transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients
AT osakiyukio transcatheterarterialchemoembolizationforintermediatestagehepatocellularcarcinomaclinicaloutcomeandsafetyinelderlypatients